Can long-term outcomes be improved by shortening the duration of untreated illness in psychiatric Disorders? a conceptual framework

Psychopathology

Volumn 46, Issue 1, 2013, Pages 14-21

  Dell'Osso, Bernardo ^a   Glick, Ira D ^b   Baldwin, David S ^c   Altamura, A Carlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Affective disorders; Duration of untreated illness; Duration of untreated psychosis; Schizophrenia

Indexed keywords

EID: 84870383952     PISSN: 02544962     EISSN: None     Source Type: Journal    
DOI: 10.1159/000338608     Document Type: Review

References (72)

1. Breitborde NJK, Srihari VH, Woods SW: Review of the operational definition for firstepisode psychosis. Early Interv Psychiatry 2009; 3: 259-265.
2. Compton MT, Carter T, Bergner E, Franz L, Stewart T, Trotman H, McGlashan TH, Mc- Gorry PD: Defining, operationalizing, and measuring the duration of untreated psychosis: advances, limitations and future directions. Early Interv Psychiatry 2007; 1: 236- 250.
3. Dell'Osso B, Altamura AC: Duration of untreated psychosis and duration of untreated illness: new vistas. CNS Spectr 2010; 15: 238- 246.
4. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T: Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975-983. (Pubitemid 41248376)
5. Perkins DO, Gu H, Boteva K, Lieberman JA: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and metaanalysis. Am J Psychiatry 2005; 162: 1785- 1804. (Pubitemid 41428609)
6. McGlashan T: Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 1999; 46: 899-907. (Pubitemid 29452981)
7. Barnes TR, Hutton SB, Chapman MJ, Mutsatsa S, Puri BK, Joyce EM: West London first-episode study of schizophrenia. Clinical correlates of duration of untreated psychosis. Br J Psychiatry 2000; 177: 207-211.
8. Penttilä M, Jääskeläinen E, Haapea M, Tanskanen P, Veijola J, Ridler K, Murray GK, Barnes A, Jones PB, Isohanni M, Koponen H, Miettunen J: Association between duration of untreated psychosis and brain morphology in schizophrenia within the Northern Finland 1966 Birth Cohort. Schizophr Res 2010; 123: 145-152.
9. Goldberg TE, Burdick KE, McCormack J, Napolitano B, Patel RC, Sevy SM, Goldman R, Lencz T, Malhotra AK, Kane JM, Robinson DG: Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophr Res 2009; 107: 262-266.
10. Altamura AC, Bobo WV, Meltzer HY: Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol 2007; 22: 249-267. (Pubitemid 47237544)
11. Häfner H, Löffler W, Maurer K, Hambrecht M, van der Heiden W: Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand 1999; 100: 105-118. (Pubitemid 29372527)
12. Large M, Nielssen O, Slade T, Harris A: Measurement and reporting of the duration of untreated psychosis. Early Interv Psychiatry 2008; 2: 201-211.
13. Jeppesen P, Petersen L, Thorup A, Abel MB, Øhlenschlaeger J, Christensen TØ, Krarup G, Jørgensen P, Nordentoft M: The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med 2008; 38: 1157-1166. (Pubitemid 351950154)
14. Schimmelmann BG, Huber CG, Lambert M, Cotton S, McGorry PD, Conud P: Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008; 42: 982-990.
15. Ghaemi SN, Boiman EE, Goodwin FK: Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000; 61: 804-808.
16. Kohn R, Safena S, Levav I, Saraceno B: The treatment gap in mental health care. Bull World Health Organ 2004; 11: 858-866. (Pubitemid 39573744)
17. Freidl M, Piralic Spitzl S, Aigner M: How depressive symptoms correlate with stigma perception of mental illness. Int Rev Psychiatry 2008; 20: 510-514.
18. Franz L, Carter T, Leiner AS, Bergner E, Thompson NJ, Compton MT: Stigma and treatment delay in first-episode psychosis: a grounded theory study. Early Interv Psychiatry 2010; 4: 47-56.
19. O'Callaghan E, Turner N, Renwick L, Jackson D, Sutton M, Foley SD, McWilliams S, Behan C, Fetherstone A, Kinsella A: First episode psychosis and the trail to secondary care: help-seeking and health-system delays. Soc Psychiatry Psychiatr Epidemiol 2010; 45: 381-391.
20. Altamura AC, Dell'Osso B, Berlin HA, Buoli M, Bassetti R, Mundo E: Duration of untreated illness and suicide in bipolar disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci 2010; 260: 385-389.
21. Craig TJ, Bromet EJ, Fennig S, Tanenberg- Karant M, Lavelle J, Galambos N: Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry 2000; 157: 60-66. (Pubitemid 30027422)
22. Altamura AC, Santini A, Salvadori D, Mundo E: Duration of untreated illness in panic disorder: a poor outcome risk factor? Neuropsychiatr Dis Treat 2005; 1: 345-347.
23. Wagner R, Silove D, Marnane C, Rouen D: Delays in referral of patients with social phobia, panic disorder and generalized anxiety disorder attending a specialist anxiety clinic. J Anxiety Disord 2006; 20: 363-371.
24. Altamura AC, Dell'Osso B, D'Urso N, Russo M, Fumagalli S, Mundo E: Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectr 2008; 13: 415-422. (Pubitemid 351792224)
25. Dell'Osso B, Buoli M, Hollander E, Altamura AC: Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder. World J Biol Psychiatry 2010; 11: 59-65.
26. Singh SP: Outcome measures in early psychosis; relevance of duration of untreated psychosis. Br J Psychiatry 2007; 50:s58-s63. (Pubitemid 47204557)
27. Olney JW, Farber NB: Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
28. Coyle JT: The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996; 3: 241-253. (Pubitemid 26058365)
29. Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E: The anatomy of firstepisode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am J Psychiatry 2008; 165: 1015-1023.
30. Salisbury DF, Kuroki N, Kasai K, Shenton ME, McCarley RW: Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry 2007; 64: 521-529. (Pubitemid 46718285)
31. Lawrie SM, McIntosh AM, Hall J, Johnstone EC: Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull 2008; 34: 330-340. (Pubitemid 351323338)
32. Hulshoff Pol HE, Kahn RS: What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008; 34: 354-366. (Pubitemid 351323347)
33. Cahn W, Rais M, Stigter FP, van Haren NE, Caspers E, Hulshoff Pol HE, Xu Z, Schnack HG, Kahn RS: Psychosis and brain volume changes during the first five years of schizophrenia. Eur Neuropsychopharmacol 2009; 19: 147-151.
34. Koolschijn PC, van Haren NE, Lensvelt- Mulders GJ, Hulshoff Pol HE, Kahn RS: Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp 2009; 30: 3719-3735.
35. Vita A, De Peri L, Sacchetti E: Gray matter, white matter, brain and intracranial volumes in first-episode bipolar disorder: a metaanalysis of magnetic resonance imaging studies. Bipolar Disord 2009; 11: 807-814.
36. Pittenger C, Duman RS: Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008; 33: 88-109. (Pubitemid 350191319)
37. Lopez-Larson M, Breeze JL, Kennedy DN, Hodge SM, Tang L, Moore C, Giuliano AJ, Makris N, Caviness VS, Frazier JA: Age-related changes in the corpus callosum in early- onset bipolar disorder assessed using volumetric and cross-sectional measurements. Brain Imaging Behav 2010; 4: 220-231.
38. Chan WY, Yang GL, Chia MY, Woon PS, Lee J, Keefe R, Sitoh YY, Nowinski WL, Sim K: Cortical and subcortical white matter abnormalities in adults with remitted first-episode mania revealed by Tract-Based Spatial Statistics. Bipolar Disord 2010; 12: 383-389.
39. Bora E, Fornito A, Yücel M, Pantelis C: Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biol Psychiatry 2010; 67: 1097-1105.
40. Salvadore G, Drevets WC, Henter ID, Zarate CA, Manji HK: Early intervention in bipolar disorder. 2.
41. Therapeutics. Early Interv Psychiatry 2008; 2: 136-146.
42. Dell'Osso B, Buoli B, Baldwin DS, Altamura AC: Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol 2010; 25: 17-29.
43. Harrison BJ, Soriano-Mas C, Pujol J, Ortiz H, López-Solà M, Hernández-Ribas R, Deus J, Alonso P, Yücel M, Pantelis C, Menchon JM, Cardoner N: Altered corticostriatal functional connectivity in obsessive-compulsive disorder. Arch Gen Psychiatry 2009; 66: 1189-1200.
44. Duran FL, Hoexter MQ, Valente AA Jr, Miguel EC, Busatto GF: Association between symptom severity and internal capsule volume in obsessive-compulsive disorder. Neurosci Lett 2009; 452: 68-71.
45. Nitschke JB, Sarinopoulos I, Oathes DJ, Johnstone T, Whalen PJ, Davidson RJ, Kalin NH: Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry 2009; 166: 302-310.
46. Altamura AC, Buoli M, Albano A, Dell'Osso B: Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study. Int Clin Psychopharmacol 2010; 25: 172-179.
47. Harris MG, Henry LP, Harrigan SM, Purcell R, Schwartz OS, Farrelly SE, Prosser AL, Jackson HJ, McGorry PD: The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res 2005; 79: 85-93. (Pubitemid 41362596)
48. Altamura AC, Bassetti R, Sassella F, Salvatori D, Mundo E: Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res 2001; 52: 29-36. (Pubitemid 32947045)
49. Altamura AC, Bassetti R, Bignotti S, Pioli R, Mundo E: Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res 2003; 60: 47-55. (Pubitemid 36015787)
50. Lappin JM, Morgan KD, Morgan C, Dazzan P, Reichenberg A, Zanelli JW, Fearon P, Jones PB, Lloyd T, Tarrant J, Farrant A, Leff J, Murray RM: Duration of untreated psychosis and neuropsychological function in first episode psychosis. Schizophr Res 2007; 95: 103-110. (Pubitemid 47313637)
51. Melle I, Larsen TK, Haahr U, Friis S, Johannesen JO, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan T: Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry 2008; 65: 634- 640. (Pubitemid 351787234)
52. Jibson MD, Glick ID, Tandon RT: Schizophrenia and other psychotic disorders. Focus 2004; 2: 17-30.
53. Clarke M, Whitty P, Browne S, Mc Tigue O, Kinsella A, Waddington JL, Larkin C, O'Callaghan E: Suicidality in first episode psychosis. Schizophr Res 2006; 86: 221-225. (Pubitemid 44251277)
54. Barrett EA, Sundet K, Faerden A, Nesvåg R, Agartz I, Fosse R, Mork E, Steen NE, Andreassen OA, Melle I: Suicidality before and in the early phases of first episode psychosis. Schizophr Res 2010; 119: 11-17.
55. Altamura AC, Dell'Osso B, Mundo E, Dell'Osso L: Duration of untreated illness in major depressive disorder: a naturalistic study. Int J Clin Pract 2007; 61: 1697-1700. (Pubitemid 47404387)
56. Gormley N, O'Leary D, Costello F: First admissions for depression: is the 'no-treatment interval' a critical predictor of time to remission? J Affect Disord 1999; 54: 49-54. (Pubitemid 29287672)
57. de Diego-Adelino J, Portella MJ, Puidgemont D, Pérez-Egea R, Alvarez E, Pérez V: A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. J Affect Disord 2010; 120: 221-225.
58. Altamura AC, Dell'Osso B, Vismara S, Mundo E: May duration of untreated illness influence the long-term course of major depressive disorder? Eur Psychiatry 2008; 23: 92-96.
59. Okuda A, Suzuki T, Kishi T, Yamanouchi Y, Umeda K, Haitoh H, Hashimoto S, Ozaki N, Iwata N: Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci 2010; 64: 268-273.
60. Marchall M, Rathbone J: Early intervention in psychosis. Cochrane Database Syst Rev 2006; 4:CD004718.
61. Francey SM, Nelson B, Thompson A, Parker AG, Kerr M, Macneil C, Fraser R, Hughes F, Crisp K, Harrigan S, Wood SJ, Berk M, Mc- Gorry PD: Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res 2010; 119: 1-10.
62. Liu P, Parker AG, Hetrick SE, Callahan P, de Silva S, Purcell R: An evidence map of interventions across premorbid, ultra-high risk and first episode phases of psychosis. Schizophr Res 2010; 123: 37-44.
63. Yung AR, Nelson B, Thompson AD, Wood SJ: Should a 'Risk Syndrome for Psychosis' be included in the DSMV? Schizophr Res 2010; 120: 7-15.
64. Larson MK, Walker EF, Compton MT: Early signs, diagnosis and therapeutic of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother 2010; 10: 1347-1359.
65. Piontkewitz Y, Arad M, Weiner I: Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull 2011; 37: 1257-1269.
66. Josiassen RC, Shaughnessy RA, Filymer DM, Donohue AM, Kacso M, Finkel N, Curtis J, Audino B, Skuban N: Early intervention with second generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study. Early Interv Psychiatry 2010; 4: 57-63.
67. Meulenbeek P, Willemse G, Smit F, van Balkom A, Spinhoven P, Cuijpers P: Early intervention in panic: pragmatic randomised controlled trial. Br J Psychiatry 2010; 196: 326-331.
68. Meulenbeek P, Spinhoven P, Smit F, van Balkom A, Cuijpers P: Cognitive mediation of panic reduction during an early intervention for panic. Acta Psychiatr Scand 2010; 122: 20-29.
69. Roberts NP, Kitchiner NJ, Bisson JL: Early psychological interventions to treat acute traumatic stress symptoms. Cochrane Database Syst Rev 2010; 3:CD007944.
70. Minde K, Roy J, Bezonsky R, Hashemi A: The effectiveness of CBT in 3- to 7-year-old anxious children: preliminary data. J Can Acad Child Adolesc Psychiatry 2010; 19: 109-115.
71. Neil AL, Christensen H: Australian schoolbased prevention and early intervention programs for anxiety and depression: a systematic review. Med J Aust 2007; 186: 305-308. (Pubitemid 46534236)
72. Christensen H, Pallister E, Smale S, Hickie IB, Calear AL: Community-based prevention programs for anxiety and depression in youth: a systematic review. J Prim Prev 2010; 31: 139-170.